Dow Jones

38,919.13

0.17%

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
NASDAQ
Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM) (APCVZ)
Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM) (APCVZ) Noticias

APCVZ

Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM) (APCVZ)

Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:APCVZ

1 2 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
07/03/2011	13:58	Business Wire	Fresenius Kabi Pharmaceuticals Holding, Inc. Files Form 25 to Delist & Deregister Contingent Value Rights for APP Pharmaceuti...	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
23/02/2011	05:04	Edgar (US Regulatory)	Current report filing (8-K)	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
23/02/2011	05:04	Edgar (US Regulatory)	Annual Report (10-K)	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
23/02/2011	00:01	Business Wire	Fresenius Kabi Pharmaceuticals Holding, Inc. Files Form 10-K for APP Pharmaceuticals, Inc. (APP)	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
26/01/2011	07:00	Business Wire	APP Pharmaceuticals Announces Agreement with Teva Pharmaceuticals to Manufacture and Market Gemcitabine HCI for Injection	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
30/11/2010	00:01	Business Wire	APP Pharmaceuticals Announces Approval and Launch of Topotecan for Injection	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
05/11/2010	14:39	Business Wire	APP Pharmaceuticals to Launch Drug Hotline	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
02/11/2010	05:04	Edgar (US Regulatory)	Quarterly Report (10-Q)	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
01/11/2010	19:16	Business Wire	Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-Q	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
29/10/2010	17:53	Business Wire	APP Pharmaceuticals Announces Approval of Metoprolol Tartrate Injection, USP	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
06/07/2010	00:01	Business Wire	APP Pharmaceuticals Announces Marketing Clearance of Preservative-Free Heparin Lock Flush Solution, USP	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
29/06/2010	13:44	Edgar (US Regulatory)	Annual Report of Employee Stock Plans (11-K)	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
29/06/2010	00:01	Business Wire	APP Pharmaceuticals to Market Anastrozole Tablets in the U.S.	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
22/06/2010	00:01	Business Wire	APP Pharmaceuticals Announces Approval of Ganciclovir for Injection, USP	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
21/06/2010	00:01	Business Wire	APP Pharmaceuticals Announces Approval and Launch of First Generic Aztreonam for Injection, USP	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
11/06/2010	00:01	Business Wire	APP Pharmaceuticals to Market Oxaliplatin Injection (Liquid) in the U.S.	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
08/06/2010	00:01	Business Wire	APP Pharmaceuticals Receives Approval for Lyophilized Oxaliplatin for Injection	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
01/04/2010	10:39	Business Wire	Fresenius Kabi Enters Into Licensing and Settlement Agreements with sanofi-aventis	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
31/03/2010	16:27	Edgar (US Regulatory)	Amended Annual Report (10-K/A)	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
25/03/2010	08:15	GlobeNewswire Inc.	Emerging Stock Report Initiates Independent Research Coverage on Fresenius Kabi Pharmaceuticals Holding, Inc.	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
23/03/2010	00:01	Business Wire	APP Pharmaceuticals Receives Approval for Indomethacin for Injection	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
23/02/2010	19:08	Business Wire	Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-K	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
02/12/2009	15:01	Business Wire	Thomas H. Silberg to Retire as President and CEO of APP Pharmaceuticals, John Ducker Named as Successor	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
02/11/2009	18:47	Business Wire	Bernhard Hampl, Ph.D. Elected to Serve as Executive Chairman of the Board of Directors of Fresenius Kabi Pharmaceuticals Hold...	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
21/10/2009	01:00	Business Wire	APP Pharmaceuticals Receives Approval for the First Generic Chlorothiazide Sodium for Injection, USP	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
08/10/2009	00:00	Business Wire	APP Pharmaceuticals Receives Approval for Sumatriptan Succinate Injection, USP	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
01/10/2009	13:40	Business Wire	APP Pharmaceutical Supports New USP Standards for Unfractionated Heparin	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
17/09/2009	00:00	Business Wire	APP Pharmaceuticals Receives Approval for Deferoxamine Mesylate for Injection, USP	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
25/08/2009	00:00	Business Wire	APP Pharmaceuticals Receives Approval for Penicillin G Potassium for Injection, USP	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)
10/08/2009	01:00	Business Wire	APP Pharmaceuticals Receives Approval for Idarubicin HCI Injection	NASDAQ:APCVZ	Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM)